These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 8483888)
1. Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. Frisman DM; McCarthy WF; Schleiff P; Buckner SB; Nocito JD; O'Leary TJ Mod Pathol; 1993 Mar; 6(2):179-84. PubMed ID: 8483888 [TBL] [Abstract][Full Text] [Related]
2. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions. Friedman MT; Gentile P; Tarectecan A; Fuchs A Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609 [TBL] [Abstract][Full Text] [Related]
3. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Comin CE; Novelli L; Boddi V; Paglierani M; Dini S Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372 [TBL] [Abstract][Full Text] [Related]
4. Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry. Tickman RJ; Cohen C; Varma VA; Fekete PS; DeRose PB Acta Cytol; 1990; 34(4):491-6. PubMed ID: 2197840 [TBL] [Abstract][Full Text] [Related]
5. [Comparative study of the expression of CEA and a myelomonocytic antigen (CD15) in serous effusions using two monoclonal antibodies NEO 723 and Leu M1]. Daste G; Berthier F; Mauduyt MA; Soleilhavoup JP Arch Anat Cytol Pathol; 1992; 40(4):183-9. PubMed ID: 1294046 [TBL] [Abstract][Full Text] [Related]
6. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268 [TBL] [Abstract][Full Text] [Related]
7. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry. Su XY; Li GD; Liu WP; Xie B; Jiang YH Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004 [TBL] [Abstract][Full Text] [Related]
8. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1. Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030 [TBL] [Abstract][Full Text] [Related]
9. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. Delahaye M; Hoogsteden HC; Van der Kwast TH J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800 [TBL] [Abstract][Full Text] [Related]
10. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis. Cakir E; Demirag F; Aydin M; Unsal E Diagn Cytopathol; 2009 Jan; 37(1):4-10. PubMed ID: 18973123 [TBL] [Abstract][Full Text] [Related]
11. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338 [TBL] [Abstract][Full Text] [Related]
12. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations? Deniz H; Kibar Y; Güldür ME; Bakir K Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998 [TBL] [Abstract][Full Text] [Related]
13. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877 [TBL] [Abstract][Full Text] [Related]
14. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Dejmek A; Hjerpe A Cytopathology; 2000 Feb; 11(1):8-17. PubMed ID: 10714371 [TBL] [Abstract][Full Text] [Related]
15. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Dejmek A; Hjerpe A Diagn Cytopathol; 2005 Mar; 32(3):160-6. PubMed ID: 15690331 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin. Duggan MA; Masters CB; Alexander F Acta Cytol; 1987; 31(6):807-14. PubMed ID: 2447718 [TBL] [Abstract][Full Text] [Related]
17. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion]. Su XY; Li GD; Liu HB; Jiang LL Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932 [TBL] [Abstract][Full Text] [Related]
18. Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion. Ueda J; Iwata T; Ono M; Takahashi M Diagn Cytopathol; 2006 Jan; 34(1):6-10. PubMed ID: 16355377 [TBL] [Abstract][Full Text] [Related]
19. [Carcinoembryonic antigen in pleural effusion. Adenocarcinoma versus mesothelioma]. Supervía A; Guitart AC; Rubio J; Cornudella R Rev Clin Esp; 1992 Feb; 190(2):69-71. PubMed ID: 1561440 [TBL] [Abstract][Full Text] [Related]
20. Cytology, immunopathology and flow cytometry in the diagnosis of pleural and peritoneal effusions. Croonen AM; van der Valk P; Herman CJ; Lindeman J Lab Invest; 1988 Jun; 58(6):725-32. PubMed ID: 3288807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]